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Objective: Neutropenia developed after continuous intravenous infusion of ritodrine hydrochloride
(Yutopar) for preterm uterine contractions in a twin pregnancy. We successfully returned the low
neutrophil count to the normal range after discontinuation of infusion of ritodrine and treatment with
granulocyte colony stimulating factor (G-CSF).
Case Report: A 34-year-old woman with twin pregnancy was treated with ritodrine for preterm uterine
contractions at 27 weeks and 6 days gestation. Neutropenia developed after continuous intravenous
infusion of ritodrine for about 4 weeks. We ceased the ritodrine infusion immediately and treated the
neutropenia with G-CSF. A cesarean delivery was performed the day after cessation of the ritodrine
infusion because of uncontrolled preterm labor. There were no adverse side effects or infectious com-
plications in the mother or the newborns. The maternal neutrophil count recovered to the normal range
4 days after administration of G-CSF.
Conclusion: Based on prior case reports and the clinical presentation of our case, G-CSF may be a useful
treatment for pregnant women with ritodrine-induced neutropenia. However, more clinical studies are
required to conﬁrm the safety and efﬁcacy of this treatment.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Ritodrine hydrochloride is the most commonly tocolytic agent
to treat preterm uterine contractions. It is a b2 symphatomimetic
agent that is known to inhibit uterine contractions effectively in
preterm labor. Ritodrine also inﬂuences the fetus because of its
biochemical mechanism. It can pass rapidly through the placental
barrier to the fetal circulatory system [1]. The adverse effects in the
fetus include hyperinsulinemia, hypoglycemia [2], increased birth
weight, cardiac septal hypertrophy [3], and neutropenia [1]. There
are some maternal complications, such as tachycardia [4], cardio-
vascular side effects [5], acute hepatitis [6], pulmonary edema [7],
rhabdomyolysis [8], and, rarely, neutropenia [9,10]. We present theand Gynecology, Tri-Service
5F, 325, Section 2, Cheng-
bstetrics & Gynecology. Publishedcase of a pregnant woman with preterm uterine contractions
treated with ritodrine. The adverse effects in this patient included
tachycardia and shortness of breath. Neutropenia developed
without fever or other toxic signs. We prescribed granulocyte col-
ony stimulating factor (G-CSF) for treatment of her neutropenia.Case Presentation
A 34-year-old woman, gravida 1 para 0, presented to our ob-
stetric emergency department with intermittent lower abdominal
pain at 27weeks 6 days of gestationwith a twin pregnancy. Shewas
healthy in the past without speciﬁc medical history. The tocody-
namometer showed preterm uterine contractions. She was
admitted to our ward for tocolytic treatment. Previous history
showed that she had a twin pregnancy after in vitro fertilization. At
about 23 weeks of gestation, an advanced obstetric ultrasound was
performed. A shortened cervical length with near-full dilation of
the cervix was observed. She then underwent cerclage of the cervix.by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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Tablets 10 mg) was prescribed at two pills every 4 hours until the
day she presented to our emergency department.
During her hospitalization, ritodrine was administered intra-
venously under close fetal monitoring. We adjusted the dosage of
the continuous ritodrine infusion according to the frequency and
strength of uterine contractions. Themaximal dosage of continuous
ritodrine infusionwas 7.2 mg/h (with a total dose of 5400 mg up to
the day ritodrine was ceased). The patient complained of tachy-
cardia and shortness of breath after the infusion of ritodrine, which
she could tolerate under our conservative treatment. Due to the
strong uterine contractions, we shortened the interval of betame-
thasone to 12 mg every 12 hours for 2 doses and repeated once a
week to promote thematuration of the fetal respiratory system.We
also administered prophylactic antibiotic agents with intravenous
Ampicillin 1 g every 4 hours for prevention of neonatal infection
due to unknown data of Group B Streptococcus infection.
The initial white blood cell count was about 17.0 109/L. Sub-
sequent blood analysis revealed leukocytopenia after 32 days of
ritodrine infusionwith a white blood cell count of about 1.01 109/
L and neutrophil count of about 0.33 109/L. We repeated the
blood analysis 2 days later, which showed an exacerbated neu-
tropenia with a neutrophil count of about 0.05 109/L. The
following G-CSF 300 mg was administered subcutaneously once
daily andwe ceased ritodrine infusion simultaneously. According to
the severe neutropenia, we shifted prophylactic antibiotics to
intravenous Ceftriaxone 2.0 g once daily. Even though there are
other tocolytic agents for preterm uterine contractions, the mother
and her family decided to stop tocolysis and we ceased the infusion
of ritodrine. However, an emergency cesarean section was per-
formed the day after we stopped the ritodrine infusion because of
uncontrolled preterm labor. Two female babies were delivered at
32weeks and 2 days of gestationwithweights of 1468 g and 1566 g.
Their Apgar scores were 6 points and 8 points 1 minute after birth
and rose to 8 points and 9 points 5 minutes after birth. There were
no immediate complications or morbidities such as neutropenia or
neonatal infections in the babies. The subcutaneous G-CSF was
administered for a total of 4 days. The maternal white blood cell
count increased to 3.57 109/L with 0% neutrophils on day 4 after
treatment with G-CSF. Two days later, the white blood cell count
was 32.23 109/L with 21.2% neutrophils. The patient and her ba-
bies were discharged without infectious complications.
Discussion
Preterm birth is one of the leading causes of morbidity and
mortality in neonatal fetuses. It also leads to episodes of infection
such as endometritis in postpartummothers. Of the current clinical
treatments for preterm uterine contractions, ritodrine hydrochlo-
ride is one of the most commonly selected and effective agents [11].
As a consequence of its wide use in the clinical management of
preterm uterine contractions, various maternal side effects of
ritodrine infusion have been reported. The most common side ef-
fects reported are tachycardia, pulmonary edema, and hypergly-
cemia. Ritodrine-induced neutropenia is very rare and this is the
ﬁrst case in our hospital. In our review of literatures, betametha-
sone could induce leukocytosis and there are no existing data
supporting that betamethasone can cause neutropenia. Ritodrine-
induced neutropenia was ﬁrst listed in 1986 as a possible side ef-
fect in mothers treated with ritodrine [12]. However, the number of
articles published in English concerning ritodrine-induced neu-
tropenia is extremely small.
In general, medical experience, recombinant G-CSF has been
widely used in patients with neutropenia. G-CSF is also the treat-
ment for drug-induced neutropenia [13], but the safety and efﬁcacyof G-CSF has not been established in pregnant women with drug-
induced neutropenia. The ﬁrst administration of G-CSF to preg-
nant women can be traced back to 1994 in a report by Kikkawa et al
[11], who reported successful treatment with G-CSF of three
pregnant women with ritodrine-induced neutropenia. The average
period of continuous ritodrine infusion in these three cases was
30.3 days. After treatment with G-CSF, the neutropenia recovered
within an average of 4.3 days. There was no maternal or neonatal
infectious morbidity or adverse effects.
Agranulocytosis induced by drugs may have toxic or immuno-
logical mechanisms [14]. Yasuda et al [15] reported two cases of
pregnant women treated with ritodrine who developed neu-
tropenia that could have had either toxic or immunological mech-
anisms. They considered that the patient treatedwith a higher dose
had a toxic mechanism, while the mechanism in a patient treated
with a lower dose was thought to be immunological. According to
their review of the literature, the toxic mechanism could be
mediated by a reduction in the production of granulocytes, and
should be dose dependent (at least 500 mg) and associated with a
prolonged period of administration (at least 26 days) [15]. Other
case reports indicated that ritodrine-induced neutropenia devel-
oped about 3e5 weeks after starting administration [11,16]. An
immunological mechanism could be identiﬁed by the drug
lymphocyte stimulation test, challenge tests, or skin tests [17].
From our case report and a review of the literature, we suggest
that white blood cell counts and evaluation of infectious episodes
(C-reactive protein or procalcitonin) should be checked regularly
every 2e3 weeks. Furthermore, because of the immune suppres-
sion in pregnancy, it was suggested that G-CSF should be admin-
istered to women with preterm labor who have ritodrine-induced
neutropenia, especially because the causes of preterm labor are
usually associatedwith infections [11]. Even though one case report
showed spontaneous recovery of ritodrine-induced neutropenia
after early cessation of ritodrine infusion without G-CSF adminis-
tration [18], it was strongly suggested that G-CSF should be given
immediately to prevent further infections. The most frequently
suggested dose was 100 mg once daily for 3e7 days after the
diagnosis of neutropenia [11,19]. In our case, a leukocytosis was
observed after the administration of G-CSF at a dose of 300 mg once
daily for 4 days. This may have been caused by an overdose of G-
CSF. Once ritodrine-induced neutropenia has occurred, the use of
ritodrine infusions in subsequent pregnancies should be avoided.
Fortunately, there are alternative treatments for preterm uterine
contractions, such as atosiban (oxytocin inhibitor), which has been
demonstrated to have equal efﬁcacy to ritodrine with fewer
adverse side effects [20]. If possible, a regular check of white blood
cell counts or drug lymphocyte stimulation test should be per-
formed before administration of ritodrine. Further studies are
needed to establish the standard management in this clinical
condition.Conﬂicts of interest
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